This phase II study evaluated the response rate and toxicity of single-agent gemcitabine in 40 women with epithelial ovarian cancer, previously treated with platinum-based chemotherapy. Patients had stage III or IV disease and progressive disease 1-12 months after the last treatment. Gemcitabine 1250 mg/m 2 was administered on days 1, 8 and 15 of each 28-day cycle as a 30-minute infusion.
Introduction
Gemcitabine is a nucleoside analog with substantial activity in a wide range of tumors. The present study was designed for patients with epithelial ovarian cancer previously treated with platinum-based chemotherapy and progression while on treatment or recurrent disease after a treatment-free interval. The objective of the study was to determine the objective response rate and toxicity to single-agent gemcitabine at a higher dose than used in earlier studies [1] .
Patients and methods

Patients
Eligible patients had epithelial ovarian cancer, FIGO (International Federation of Gynaecology and Obstetrics) stage III, IV, not amenable to surgery or radiotherapy. Previous treatment consisted of one or two platinum-based regimens (the first given after initial surgery). All patients had progressive disease while on treatment or 1-12 months after the last treatment. Patients were aged 18-75 years, with clinically measurable disease (not to be followed by physical examination alone), a WHO performance status < 2 and an adequate bone marrow (leukocytes 3= 3.5 x 10 9 /l, thrombocytes 5s 100 x io 9 /l, hemoglobin > 6.2 mmol/1). Patients were excluded if they had previously received a taxane, prior radiation to the measurable lesion or had inadequate liver or renal function (creatinine > 132 umol/l), CNS metastases or an active uncontrolled infection.
The study had local ethics committee approval and all patients gave written informed consent.
Trial design
This non-randomized study was performed in 40 patients enrolled in eight centers. Pre-treatment evaluation included medical history, physical and gynecological examination, assessment of measurable lesions by ultrasound, CT scan or MRI, evaluation of performance status, measurement of serum CA 125, and completion by the patients of the EORTC-QLQ-C30 quality of life questionnaire [2] ,
Treatment plan
Gemcitabine 1250 mg/m 2 was administered days 1, 8 and 15 of each 28-day cycle as a 30-minute infusion. Treatment was continued as long as this was in the best interest of the patient or until disease progression or severe toxicity occurred. The EORTC QLQ-C30 was used prior to the start of each cycle of therapy.
Doses were reduced by 25% in case of a white blood cell count (WBC) between 1 and 2 x 1O 9 /1 and/or the platelets 50-100 x 1O 9 /1. If the WBC was between 0.5 and 1 x 1O 9 /I and/or the platelet count was between 25 and 50 x 1O 9 /I the dose was omitted. If the WBC and/or the platelet counts were below these limits, therapy was either omitted or patients were removed from the study. For WHO grade 3 nonhematological toxicity the dose was either reduced by 50% or omitted, depending on best clinical judgement. Patients with WHO grade 4 nonhematological toxicity were put on hold.
Efficacy analysis
Before each cycle gynecological examination, performance status, CA 125 level and toxicity were determined. Before every second cycle, patients underwent imaging studies for tumor measurement.
Tumor response definitions were based on standard WHO criteria. Time to progressive disease was measured from the time of initial administration of gemcitabine until the time of documented disease progression, as measured by CT, MRI or ultrasound. CA 125 analysis CA 125 response was defined as follows: complete response, decrease in C/*. 125 to < 30 U/ml; partial response, a greater than 50% decrease in CA 125; progression, increase in serum CA 125 >25%. Patients were not evaluable if their CA 125 was < 30 U/ml at baseline.
Statistical analysis
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Results
Forty
Response
Four patients were not evaluable for response: two because of early progressive disease, one with brain metastases after cycle 1, and one patient who refused further treatment for unknown reasons after one cycle. Out of 36 patients that received adequate treatment, two had complete responses and six partial responses, for an overall response rate of 22% (95% CI: 10-39%). Seventeen patients had stable disease (47%), and 11 (31%) progressive disease. The overall response rate was 20% on an intention-to-treat basis. Table 2 shows the tumor characteristics of responders. Median response duration was 9 months (range 5-20).
Twenty-four out of 40 patients were evaluable for CA 125 response. Three out of 24 (13%) had a CA 125 complete response, nine patients (38%) had a CA 125 partial response, resulting in a overall CA 125 response rate of 50%. Nine patients (38%) were stable on CA 125 and three (13%) had progression.
Survival
Thirty-six patients progressed, median time to progression was 3.6 months (95% CI: 2-5 months). Thirty-four patients died: median survival time was 9 months (95% CI: 6-13 months). The one-year survival probability was 40% (95% CI: 24-56%).
Quality of life
Twenty-nine patients completed at least one post-baseline questionnaire and were analyzed. Using a paired /-test, mean endpoint (i.e., last observation) scores were compared to mean baseline scores. Significant differences (P < 0.05) were noted only in physical functioning, fatigue, dyspnea, and appetite loss, all of which worsened.
Toxicity profile
No grade 4 toxicity was seen. The incidence of worst grade 3 toxicity was: hemoglobin (13% of patients), leukopenia (16%), neutropenia (21%), and thrombocytopenia (3%), constipation (3%), fever (3%), alopecia (3%), and nausea and vomiting (18%). No grade 3 liver or renal toxicity was seen with the exception of alkaline phosphatase (3% grade 3). Although only 13% of patients experienced grade 3 toxicity for hemoglobin, 40% of patients received at least one blood transfusion. One patient discontinued the study due to severe asthenia, probably treatment related.
Discussion
The present study confirms that gemcitabine is active and well tolerated in patients with previously treated ovarian cancer and a poor prognosis. The response rate of gemcitabine of 22% in our study is noteworthy and consistent with response rates in other studies [1, 3] . Responses found with other drugs such as topotecan (21%) and paclitaxel (13%) in a similar patient population are comparable [4] .
Our data indicate that there is no cross-resistance to platinum as some of the responses were observed in platinum-refractory patients (Table 2 ). This is in accordance with observations in previous studies [1, 3] . The tolerability of gemcitabine appeared not to be influenced by the higher dose of 1250 mg/m 2 . The emetogenic potential of the drug was moderate and none of the patients showed complete loss of hair.
Gemcitabine is as active in second line as topotecan and paclitaxel but appears to be less toxic. For these reasons we conclude that gemcitabine represents an attractive drug for patients with recurrent disease. Little information is available about gemcitabine in patients with recurrent disease previously treated with a taxanebased combination, but in these cases the drug appears to be active too [5] .
Due to the favorable toxicity profile and the non cross-resistance to platinum, gemcitabine is a good candidate to be used in initial combination chemotherapy. Currently, studies are underway evaluating the combined treatment with platinum analogs and paclitaxel in untreated patients.
